A biotechnology company developing stem cell therapies to treat neurodegenerative diseases
Our proprietary technology converts mesenchymal stem cells into NurOwn®, a biological drug delivery system designed to support damaged neurons
NurOwn® cells dampen the immune system and secrete growth factors that help damaged neurons survive.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
May 16, 2017BrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn® for Phase 3 ALS Study
Brainstorm is exploring the possible commencement of a program to make NurOwn® available to a limited number of patients with Amyotrophic Lateral Sclerosis (ALS, also known as motor neuron disease) through a regulatory pathway designated for an orphan drug with a good safety profile and strong efficacy signals. This program would potentially provide patients, who today face an unmet need, with access to this investigational treatment before it receives final marketing approval from the regulatory authorities.